Results 131 to 140 of about 9,990 (166)

Recurrent hemoptysis after laryngectomy-acquired hemophilia induced by laryngeal cancer surgery and chemoradiotherapy: A case report. [PDF]

World J Clin Cases
Zhao PW, Hu YS, Jiang Z, Ainiwaer M, Liu J, Chen F.   +5 more
europepmc   +1 more source

Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis. [PDF]

J Clin Invest
Zhang T, Castillo J, Louis Sam Titus ASC, Vanarsa K, Sharma V, Kureti S, Saxena R, Mohan C.   +7 more
europepmc   +1 more source

Neutrophil extracellular traps and pyroptosis: a molecular nexus linking systemic autoimmune diseases to atherosclerosis. [PDF]

Front Immunol
Du Y, Zhang L, Cheng Y, Lu S, Ou R, Deng X.   +5 more
europepmc   +1 more source

Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada. [PDF]

EJHaem
Blackman R, Chen LYC, Keating MM, Quinn J, Robinson S.   +4 more
europepmc   +1 more source

Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths. [PDF]

Sci Rep
Matsuda M, Shimomura D, Suzuki T, Tabuchi Y, Kurono H, Nishi K, Arai N, Hoshiyama Y, Kamioka M, Moriyama M, Matsumoto T.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recurrent Venous Thrombosis with a “Lupus” Coagulation Inhibitor in the Absence of Systemic Lupus

Australian and New Zealand Journal of Medicine, 1977
A young man presenting with recurrent deep venous thrombosis was found to have a lupus type coagulation inhibitor. He showed neither clinical nor serological evidence of systemic lupus. The value of the Russell viper venom coagulation time in the detection of the inhibitor is demonstrated.
L Gibson, Brian J Feery
exaly   +3 more sources

Studies on Phospholipids in the Action of a Lupus Coagulation Inhibitor

Pathology, 1975
Plasma from a patient with early manifestations of disseminated lupus erythematosus, a prolonged partial thromboplastin time with kaolin, mildly prolonged prothrombin time, and a circulating inhibitor affecting the assay of several clotting factors was investigated.
T Exner, K A Rickard, H Kronenberg
exaly   +3 more sources

Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays [PDF]

Scandinavian Journal of Clinical and Laboratory Investigation, 2018
Edoxaban is an oral direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. The effects on common coagulation assays are clinically valuable information and in certain clinical situations a quick assessment of the anticoagulant is wanted.
Andreas Hillarp, Karin Strandberg, Tomáš L Lindahl   +2 more
exaly   +3 more sources